Bio-IT World Asia 2013 will bring together life sciences, pharmaceutical, informatics and IT professionals from all over Asia and the rest of the world to one unique location. Focusing on improving human health with discoveries and advancements in information technology, the Bio-IT World Asia conference is going to showcase the innovative and disruptive technologies in the field of big data processing and analytics, genomics, molecular diagnostics and translational informatics that have a direct or indirect impact on improving the efficiency of clinical research, healthcare delivery and drug discovery.
Some of the focused topic areas include data-intensive research collaboration, cancer research, Asian population specific biomarkers, companion diagnostic tests for personalized medicine, as well as other applications of NGS technology and targeted patient recruitment for clinical trials. << less
Bio-IT World Asia 2013 will bring together life sciences, pharmaceutical, informatics and IT professionals from all over Asia and the rest of the world to one unique location. Focusing on improving human health with discoveries and advancements in information technology, the Bio-IT World Asia conference more >>
Molecular Medicine Tri-Conference Asia will present three focused conferences presenting the most significant advances in research and technology in the areas of antibody engineering, clinical trial management and molecular diagnostics.
This landmark event, which will be held in conjunction with Bio-IT World Asia 2013, will feature presentations and panel discussions featuring leading academic scientists and researchers at biotech and larger companies from across Asia, the United States and around the world.
Our intent is not only to provide a forum to display the best of Asian biomedical research, but also to unite scientists from across the continent to discuss new trends in R&D and forge new collaborations. Please join us in Singapore next May for the inaugural Molecular Medicine Tri-Conference Asia!
Track 1: Antibody Engineering Asia (May 28-29)
Track 2: Clinical Data Management and eClinical Trials (May 29-30)
Track 3: Molecular Diagnostics (May 30-31) << less
Molecular Medicine Tri-Conference Asia will present three focused conferences presenting the most significant advances in research and technology in the areas of antibody engineering, clinical trial management and molecular diagnostics.
This landmark event, which will be held in conjunction with more >>
ChinaBio® Partnering Forum is the premier life science partnering event in China. To be held May 29–30, 2013 in Beijing, the event will attract biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.
ChinaBio® Partnering Forum 2012 had more than 700 delegates from 400 companies and 22 countries, making it the largest partnering conference in China. The 2013 edition promises to be even better with top notch attendance from pharma and biotech companies as well as leading researchers from China's top universities and institutes.
The conference also features partneringONE®, enabling delegates to efficiently identify, meet and network with companies from across the life science value chain. << less
Global Partnering in China™
ChinaBio® Partnering Forum is the premier life science partnering event in China. To be held May 29–30, 2013 in Beijing, the event will attract biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two more >>
ADME & Toxicology 2013 is an international event being hosted in New Delhi, India. This event will focus on the vital role of ADME and Toxicology in identification and design of a successful drug candidate. Our array of Keynote Speakers will give presentations on all areas of ADME and Toxicology backed up by a panel of experts speaking on highly relevant and “hot” topics such as Pharmacogenomics and Drug Safety, In-silico PK/PD, Toxicity and Genotoxicity Modeling, New therapeutic targets, Metabolomics and ADME Optimization for Drug Design/Discovery.
Co-located with the ADME & Toxicology 2013 conference will be the Nanomedicine meeting. Registered delegates will have unrestricted access to both meetings ensuring a comprehensive learning and sharing experience, as well as being financially beneficial for attendees.
Keynote Speakers: - Bhupinder Bhoop, Professor, Panjab University - Yogender Gupta, Professor, All India Institute of Medical Sciences - Jyoti Paliwal, Medical Advisor, Troikaa Pharmaceuticals Limited - Matthew Segall, CEO, Optibrium Ltd << less
ADME & Toxicology 2013 is an international event being hosted in New Delhi, India. This event will focus on the vital role of ADME and Toxicology in identification and design of a successful drug candidate. Our array of Keynote Speakers will give presentations on all areas of ADME and Toxicology backed more >>
Barnett International and Cambridge Healthtech Institute's second annual Clinical Trial Oversight Summit will feature four co-located conferences covering best practices and recent trends relevant to clinical research monitoring, auditing, clinical quality assurance, site management, and vendor oversight. This four-day summit will include presentations from experts, case studies, interactive breakout discussion groups, workshops, and networking opportunities. Themes throughout will include risk-based approaches to clinical trial management, implementing quality systems-based approaches to GCP compliance, ensuring reliable study data, responding to the evolving regulatory landscape, and preparing sites and clinical research partners for inspection-readiness. << less
Barnett International and Cambridge Healthtech Institute's second annual Clinical Trial Oversight Summit will feature four co-located conferences covering best practices and recent trends relevant to clinical research monitoring, auditing, clinical quality assurance, site management, and vendor oversight. more >>
After a dozen years covering various topics for the pharmaceutical industry, the World Pharma Congress has found its niche in effectively covering the latest preclinical strategies and technologies for driving better predictions. Building on its experience covering drug targets, high-throughput screening, lead optimization, ADME and drug safety, the event is now primed to move further downstream into early formulations and drug delivery.
2013 Conference Programs:
- 2nd Annual Predictive Preclinical Models in Oncology: Challenging Cancer Heterogeneity with Reproducible and Predictive Preclinical Studies
- 6th Annual Targeting Pain with Novel Therapeutics: Translating Success from Preclinical Assays to the Clinic
- Inaugural Accelerating Development of Difficult-to-Deliver Drugs: Driving Innovation Through Effective Tools and Novel Drug Delivery Strategies
- 6th Annual Integrated Drug Safety Risk Assessments: Predicting Drug-Induced Organ Toxicities Using Functional Assays, Models and Marker
- 4th Annual Molecular Imaging in Drug Discovery and Development: Integrating Molecular Imaging Technologies to Improve Preclinical Findings << less
After a dozen years covering various topics for the pharmaceutical industry, the World Pharma Congress has found its niche in effectively covering the latest preclinical strategies and technologies for driving better predictions. Building on its experience covering drug targets, high-throughput screening, more >>
Welcome to our European Lab Automation congress and exhibition, Europe's largest event dedicated to automation within life science.
Offering over 130 scientific presentations across 7 different conference streams linked with an exhibition containing more than 150 equipment vendors, ELA aims to highlight and showcase the latest in automated instruments and workflows.
Life science researchers and professionals are presented with an unparalleled opportunity to foster technological discussions and scientific collaboration.
Registration for ELA 2013 is now open, with all conference delegates having the opportunity to attend all 7 conference streams. << less
Welcome to our European Lab Automation congress and exhibition, Europe's largest event dedicated to automation within life science.
Offering over 130 scientific presentations across 7 different conference streams linked with an exhibition containing more than 150 equipment vendors, ELA aims to highlight more >>
SELECTBIO's Translational Medicine Summit (TRM) is focused on providing an up-to-date and expansive view of the current field of RNA-based translational research and commercial activities. This summit primarily addresses business opportunities and challenges in the RNA-based translational medicine field.
The main focus of the 2013 inaugural summit is on "Translational Application of RNAs."
The goal of this summit is to bring together speakers and delegates focused on:
1. Challenges in RNA Translational Research 2. Personalized Medicine Focused on RNAs 3. Biomarker Development Focused on RNAs 4. Diagnostics Development Focused on RNAs.
Also focused in this summit is the emerging field of Epigenetics.
All registered delegates to this summit receive an electronic copy of the Select Biosciences MicroRNA, Non-Coding RNA, and Epigenetics: Research and Biomarkers 2013 Market Report [publication date: May 2013].
Who should attend:
1. Business Development Leaders from Pharma, Biotech, as well as Academic Institutions 2. Researchers Focusing on Translational Activities 3. Licensing Executives in the Biomarker and Diagnostics Fields. << less
SELECTBIO's Translational Medicine Summit (TRM) is focused on providing an up-to-date and expansive view of the current field of RNA-based translational research and commercial activities. This summit primarily addresses business opportunities and challenges in the RNA-based translational medicine more >>
Analytical Methods are essential for a number of purposes, including testing for QC release, testing of stability samples, testing of reference materials and to provide data to support specifications.
This course provides a comprehensive coverage of the method development and validation requirements that are essential to progress a pharmaceutical compound, at each stage of product development.
Upon completion of this course, delegates will have learned what is necessary to develop and validate methods for drug substance and drug product to comply with international regulatory guidelines.
The course is designed for: Scientists working with HPLC who need to further their understanding of the technique in order to develop better methods faster. Scientists who have to validate HPLC methods in accordance with current internationally-accepted guidance. HPLC technicians working in R&D laboratories, quality control laboratories and stability testing laboratories. Managers with a responsibility for generating regulatory submissions.
Analytical Methods are essential for a number of purposes, including testing for QC release, testing of stability samples, testing of reference materials and to provide data to support specifications.
This course provides a comprehensive coverage of the method development and validation requirements more >>
This established and well recognized kinase conference addresses re-occurring questions about selectivity, safety, resistance and novelty. After many years of research and therapeutic developments of kinase inhibitors, the field still offers new opportunities as novel kinases and their inhibitors are making an appearance. In addition, interest in the repurposing of already developed drugs is growing immensely.
This conference addresses questions such as what lies ahead, what is in store for the pharmaceutical industry and what new avenues are opening up in regards to technologies and methods used or in regards to novel targets and therapeutic approaches explored. Take advantage of the opportunity to present your data, concepts and results as part of a highly knowledgeable speaker faculty by submitting a speaking proposal for this event. << less
This established and well recognized kinase conference addresses re-occurring questions about selectivity, safety, resistance and novelty. After many years of research and therapeutic developments of kinase inhibitors, the field still offers new opportunities as novel kinases and their inhibitors are more >>
Mitsubishi’s Automation headquarters, Hatfield is the setting for the 1 Day – R & A show being held on 19th June.
The show will be focusing on the components and technologies used in laboratory automation applications.
It will be an opportunity to listen and discuss the implementation of automation components with colleagues and suppliers. A varied selection of full length and snapshot talks will be presented to give scientific and engineering users an understanding of what is available to automate experiments.
This conference is aimed at anyone who works in the life sciences laboratory environment and who would benefit from the implementation of these technologies. We intend to cover innovative technologies such as software for the automated process (control & data), robotic, process simulation and automation tools (vision and transportation).
We are delighted to be hosted at Mitsubishi - Robotics & Automation – going back to our roots. Join us for a really great show.
The 13th Structure-Based Drug Discovery conference will feature the development of in silico technology as well as experimental approaches useful for accurately predicting and modeling the structures of proteins in structure-based drug design efforts. In addition, examples of successful applications of such technology approaches to genome-to-drug lead investigations are showcased.
Topics to be covered may include:
- Recent research on important targets that are amenable to structure-based drug design, such as GPCRs - Design of therapeutic agents that interact with protein-protein interactions hot spots as targets - Large-scale informatics framework that integrate functional, structural and expression information for contextual drug discovery - Mining the bacterial genome for novel bioactive compounds - Epigenetics in drug discovery - Cellular environment including solvation in drug discovery - Fragment-based design - Other interesting topics << less
The 13th Structure-Based Drug Discovery conference will feature the development of in silico technology as well as experimental approaches useful for accurately predicting and modeling the structures of proteins in structure-based drug design efforts. In addition, examples of successful applications more >>
A QbD and lifecycle management approach to analytical method development and qualification will result in a better understanding and fewer failures of analytical methods due to more robust methods which produce consistent, reliable, quality data throughout the lifecycle. This, in turn, will lead to less method transfer failures, OOS results and method “incidents” when used in the routine environment. As the industry now applying Quality by Design (QbD) to process development, it is now being recognized that this is also the way forward to improve and standardise our approach to analytical procedures.
This two day training course presents a brief overview of method validation according to ICHQ2 (R1) and discusses the limitations of this approach in terms of its contribution to failure of methods with regards to method transfer and generation of OOS results later in the method lifecycle. It then illustrates that the lifecycle approach is a holistic process which embraces the philosophies of the traditional approach but results in more robust analytical procedures. Finally a comparison of the current approach (ICHQ2) and the QbD approach is presented. The course focuses on HPLC methods; therefore experience in developing, validating and transferring analytical HPLC methods would be an advantage to participants. << less
A QbD and lifecycle management approach to analytical method development and qualification will result in a better understanding and fewer failures of analytical methods due to more robust methods which produce consistent, reliable, quality data throughout the lifecycle. This, in turn, will lead to more >>
Mondial Research Group will be offering our two-day "Evaluation of ADMET Drug Properties in Drug Discovery and Development" training course on June 20th and 21st 2013 in Barcelona, Spain. The New Training Course is presented by our three expert instructors.
You may see the agenda and training description by following the link below.
The same Training will be offered again on January 28th and 29th 2014 in Brussels, Belgium.
Participants to the January training course may attend the “9th Annual International Conference on Predictive Human Toxicity and ADME Tox Studies" free of charge if you book by November 30, 2013. Follow the link below for more information on the conference.
There is a discount of 15% off of the regular training price when two attendees book together. There are also discounts available for groups over three. As seating is limited in the training course, please book early to avoid disappointment.
It would be appreciated if you could forward the email to any colleague that may be interested and post this e-mail to an internal bulletin board so that any interested colleagues may have access to the information.
Should you require more information or wish to register, please do not hesitate to contact me.
Join me on LinkedIn to keep up with all training and conference news and updates. http://www.linkedin.com/in/cristinalungu22010
Best Regards,
Cristina C. Lungu Business Development Manager/ Event Coordinator
Mondial Research Group tel +44 20 8144 7170 fax +40 21 223 6500 cristinah@mondialresearchgroup.com www.mondialresearchgroup.com << less
Mondial Research Group will be offering our two-day "Evaluation of ADMET Drug Properties in Drug Discovery and Development" training course on June 20th and 21st 2013 in Barcelona, Spain. The New Training Course is presented by our three expert instructors.
You may see the agenda and training description more >>
SMi’s 3rd Annual Biobanking conference will aim to bring together key solution providers and potential clients affiliated with pharmaceutical companies and Biobanking institutions alike.
As researchers endeavor to develop more personalised medicines, acquiring high quality biospecimens is essential. This is reflected in the estimation that the global Biobanking market is expected to reach $183 billion as biobanks experience rapid growth.
SMi’s 3rd annual Biobanking event will reflect the significant change driving current development in biosample management. There will be efforts to associate value to existing biological resources and coverage of important issues experienced by those who donate, manage and expend biobank samples. Focussing on the properties of data sharing and greater involvement between biobanks, allow Biobanking 2013 to give you the most recent up to date information on Biobanking today.
Benefits of Attending:
• Unique insights into building and developing a successful biobanking infrastructure • Explore novel technologies for managing biobanks - Radio Frequency Identification (RFID) • Promote availability and maximise value from biospecimen collections • Investigate ways in which biobanks can contribute to stratified medicines • Interactive platform for networking between academia and industry • Spotlight on ground-breaking topics that expose commercial opportunities for future investments • Highlight global regulatory, legal and ethical compliance considerations
The first 2 instalments in the Biobanking series received great feedback from the industry. Comments included Roche – “‘‘Entertaining and informative’’, Merck - ‘‘Stimulated, good discussions and provided good feedback on questions’’ and GSK - ‘‘Detailed and specific’’
To attend contact Jonathan Collins on Tel +44 (0)20 7827 6734 Email: jcollins@smi-online.co.uk
Register Online at www.smi-online.co.uk/goto/2013bio-banking-event40.asp << less
SMi’s 3rd Annual Biobanking conference will aim to bring together key solution providers and potential clients affiliated with pharmaceutical companies and Biobanking institutions alike.
As researchers endeavor to develop more personalised medicines, acquiring high quality biospecimens is essential. more >>
Bio-IT World and Cambridge Healthtech Institute are again proud to host The 2nd Annual TCGC: The Clinical Genome Conference, inviting stakeholders from all arenas impacting clinical genomics to share new findings and solutions for advancing the application of clinical genome sequencing.
TCGC brings together many constituencies for frank and vital discussion of the applications, questions and solutions surrounding clinical genome analysis, including scientists, physicians, diagnosticians, genetic counselors, bioinformaticists, ethicists, regulators, insurers, lawyers, and administrators. This 2-part event covers the science of sequencing and the business of translating genomics into the clinic. << less
Bio-IT World and Cambridge Healthtech Institute are again proud to host The 2nd Annual TCGC: The Clinical Genome Conference, inviting stakeholders from all arenas impacting clinical genomics to share new findings and solutions for advancing the application of clinical genome sequencing.
In drug development clinical pharmacology is tasked to ensure that patients receive the right dose at the right time. This ensures that the new medicine is safe and effective throughout the patient population. To achieve this goal, it is necessary to recognise the factors that can alter drug response. Knowledge of pharmacokinetics (PK) and pharmacokinetic/pharmacodynamic (PK/PD) relationships is at the heart of this endeavour. For many drugs, clinical pharmacology information accounts for almost 50% of the final drug label, further emphasising the importance of PK understanding in drug development.
Course Objective is to provide participants with an overview of the principles of PK and PK/PD modelling and how, together with regulatory guidances, they can be used to effectively deliver drug development programmes
What will participants gain? * Increased confidence to discuss PK issues within their drug projects * Understanding of the common PK terms and their importance * Understanding of how PK data influences the clinical development programme * An understanding of the factors that contribute to variability in PK * The role of PK/PD modelling in drug development * An appreciation of how regulatory guidances influence PK << less
In drug development clinical pharmacology is tasked to ensure that patients receive the right dose at the right time. This ensures that the new medicine is safe and effective throughout the patient population. To achieve this goal, it is necessary to recognise the factors that can alter drug response. more >>
SMi are proud to present the 3rd annual conference on Pharmacovigilance taking place on 1st & 2nd July 2013, London.
After recent Pharmacovigilance legislations, SMi’s conference will present the successes and failures since its implementation. 2012-2013 can be seen as year of significant change with regards to Pharmacovigilance practices and this topic has never been more of a focus for Pharmaceutical companies across the board.
With concerns occurring across the board in relation to PV auditing, companies face the challenge of understanding the key considerations when presenting to auditors. Unravel the challenges in compiling and presenting the new PSUR to external regulatory bodies and determine what these regulatory bodies have learnt in the wake of its recent introduction.
The first instalments in the Pharmacovigilance series received good reviews from the industry including Mundipharma - "Very Good", Teva Pharmaceuticals - "This was a very good conference" and PAREXEL international – “Good Speakers”
KEY REASONS TO ATTEND
• Understand the main points to consider when presenting a PSUR to external regulatory bodies. • Tackle the issues and importance of adverse event reporting. • Discuss the importance of pharmacoepidemiology and what can be learnt from global trends. • Assess the benefits and challenges involved with outsourcing pharmacovigilance processes. • Listen to case studies from companies that have undergone recent pharmacovigilance auditing and what was expected.
Join SMi as they look tackle these issues and many more at a summit that promises to be a must see event.
To Attend contact Jonathan Collins at +44 (0)207 827 6734 Email jcollins@smi-online.co.uk Register online at: http://www.smi-online.co.uk/goto/2013pharmacovigilance28.asp << less
SMi are proud to present the 3rd annual conference on Pharmacovigilance taking place on 1st & 2nd July 2013, London.
After recent Pharmacovigilance legislations, SMi’s conference will present the successes and failures since its implementation. 2012-2013 can be seen as year of significant change with more >>
Taking an international expert speaking faculty join us at SMi's Cell Culture conference due to take place on the 3 & 4 July 2013 in central London.
Cell culture is set to see huge increases in growth including the recent advances in techniques such as 3D cell culture. The cell culture market is set to be worth £4.5 billion by 2020 driven by advances in pharma and biotech. Over the two day conference delegates will be exposed to leading decision makers in a range Cell Culture related fields from Europe and the States, listen to our keynote speakers on day one speak about the latest data coming back from culture techniques being used on the International Space Station.
Day one will focus on the recent advances in 3D cell culture. Case studies will demonstrate how this method is providing highly physiologically accurate preclinical data and current approaches for culture in relevant diseases.
Day two's speaking faculty will focus on cell culture process development and cell line development including the use of high throughput technologies.
Our 3-day event, formed of two half day post-conference workshops and a two-day conference will provide useful insights into the latest developments within cell culture. << less
Taking an international expert speaking faculty join us at SMi's Cell Culture conference due to take place on the 3 & 4 July 2013 in central London.
Cell culture is set to see huge increases in growth including the recent advances in techniques such as 3D cell culture. The cell culture market is set more >>
SELECTBIO's 4th annual Single Cell Analysis Summit 2013 will build on the overwhelming success of the previous Single Cell events.
Single Cell Analysis is an up and coming area, which focuses on detecting minute differences in individual cells, which many say could improve medical tests and treatments. At this event will be a whole host of expert speakers in this field who will be able to offer and insight into the latest methods and techniques being used to image and analyse various cells. Topics that will be covered include microarrays and chips for single cell analysis, microfluidics in single cell analysis, signalling in single cell analysis and many others, designed to give delegates a comprehensive glimpse into this exciting area of science.
Call for Posters
You can present your research on a poster while attending the meeting. Submit an abstract for consideration now! Poster Submission Deadline: 12 August 2013 << less
SELECTBIO's 4th annual Single Cell Analysis Summit 2013 will build on the overwhelming success of the previous Single Cell events.
Single Cell Analysis is an up and coming area, which focuses on detecting minute differences in individual cells, which many say could improve medical tests and treatments. more >>
Each year, ImVacS brings vaccine professionals together from around the world to discuss the crucial issues surrounding vaccine development. Along with presenting a snapshot of where vaccines stand today, the meeting also provides an important venue for networking, information exchange, and establishing collaborations. The eighth annual Novel Vaccines: Innovation & Adjuvants conference explores how vaccine development is being innovated in order to create more efficacious vaccines, such as using Systems Biology or Reverse Vaccinology. The use of adjuvants - their safety and mode of action - will also be discussed, as will DNA vaccines, Toll-Like Receptors, and novel modes of delivery. In addition, how improved vaccines are targeting infectious diseases will be addressed and updated. << less
Each year, ImVacS brings vaccine professionals together from around the world to discuss the crucial issues surrounding vaccine development. Along with presenting a snapshot of where vaccines stand today, the meeting also provides an important venue for networking, information exchange, and establishing more >>
Recent advances in cancer immunotherapy have turned researcher's attentions to new therapeutic strategies focused on improved specificity, control of key checkpoints in immune response, the identification of new biomarkers and novel ways of combining therapies for maximum effect. The two-conference Immunotherapies Congress offers an exciting opportunity to learn how these strategies are being translated into the next generation of cancer immunotherapeutic drug products.
The first meeting, Emerging Cancer Immunotherapies and Vaccines (August 13-14), will examine new targets and strategies in this space, and explore how the lessons learned from early cancer vaccines are driving development of longer-lasting and more potent immune responses. A second conference, Immunomodulatory Therapeutic Antibodies for Cancer (August 14-15) showcases the exciting wave of checkpoint blockades such as anti-PD-1 and anti-CTLA-4 now in clinical development -- and explores considerations of trial design, drug safety and biomarker discovery that will influence their application in patients. << less
Recent advances in cancer immunotherapy have turned researcher's attentions to new therapeutic strategies focused on improved specificity, control of key checkpoints in immune response, the identification of new biomarkers and novel ways of combining therapies for maximum effect. The two-conference more >>
As prices continue to drop and technology continues to improve, the purchase of a next-generation sequencing (NGS) platform is now a reality for most research laboratories. Once you have purchased a platform, however, how do you maximize the greatest potential for your investment? Realizing this potential requires efficient workflow strategies, careful experimental design, comprehensive targeted enrichment technologies, data analysis, management, and integration, in addition to maintaining your platform and people management all at maximum production. The central theme at Cambridge Healthtech Institute's Sequencing Strategies for Success is efficient utilization of your NGS platform. Sessions will focus on common bottlenecks, case studies, real-world experiences and solutions from experienced NGS users. << less
As prices continue to drop and technology continues to improve, the purchase of a next-generation sequencing (NGS) platform is now a reality for most research laboratories. Once you have purchased a platform, however, how do you maximize the greatest potential for your investment? Realizing this potential more >>
Advances in next-generation sequencing and computation have elucidated the impact of human genomic variation; however, the impact of this variation is largely unexplored in the human microbiome. Now clinical and environmental researchers have the high-resolution tools to explore the emergent science of microbial communities and the ecosystems they inhabit. CHI's Dynamics of the Microbiome on Health and Disease conference focuses on understanding the role of the microbiome to offer new insights into disease processes and discovery of new therapeutic strategies. << less
Advances in next-generation sequencing and computation have elucidated the impact of human genomic variation; however, the impact of this variation is largely unexplored in the human microbiome. Now clinical and environmental researchers have the high-resolution tools to explore the emergent science more >>
The Bioprocessing Summit brings together international leaders to discuss today’s bioprocess issues from cell line selection to manufacturing. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking. This leading bioprocess meeting is hosted by Boston each summer along the lively and cosmopolitan harbor waterfront, with its restaurants, cafes, museums and art galleries, and within easy reach of historical sites, Faneuil Hall and the famed North End. << less
The Bioprocessing Summit brings together international leaders to discuss today’s bioprocess issues from cell line selection to manufacturing. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking. This leading bioprocess meeting is more >>
The Next Generation Dx Summit (Enabling Point-of-Care Diagnostics, Cancer Molecular Markers to Guide Therapy, Molecular Diagnostics for Infectious Disease, Companion Diagnostics, Commercialization of Molecular Diagnostics, Molecular Profiling of Circulating Tumor Cells) is designed to bring together all of the major players in the evolving areas of diagnostics. This year, we have assembled an impressive faculty of speakers from industry, government, and leading academic institutions. This meeting will showcase improvements in technology research and development with an emphasis on applications in the clinic and commercialization. Plan to hear what the industry leaders are saying about future market opportunities and network with your peers this August 20-22 in Washington, DC. << less
The Next Generation Dx Summit (Enabling Point-of-Care Diagnostics, Cancer Molecular Markers to Guide Therapy, Molecular Diagnostics for Infectious Disease, Companion Diagnostics, Commercialization of Molecular Diagnostics, Molecular Profiling of Circulating Tumor Cells) is designed to bring together more >>
Sequencing a genome is only the beginning. Several layers of analysis are necessary to convert raw sequence data into an understanding of functional biology. First, error sources in the original raw data from multiple platforms and diverse applications must be accounted for. Then, as computational methods for assembly, alignment and variation detection continue to advance, a broad range of genetic analysis applications including comparative genomics, high-throughput polymorphism detection, analysis of coding and non-coding RNAs and identifying mutant genes in disease pathways can be addressed. CHI’s Sequencing Data Analysis and Interpretation conference combines unique perspectives from a variety of researchers, engineers, biostatisticians and software developers involved in NGS data analysis. << less
Sequencing a genome is only the beginning. Several layers of analysis are necessary to convert raw sequence data into an understanding of functional biology. First, error sources in the original raw data from multiple platforms and diverse applications must be accounted for. Then, as computational methods more >>
Over the past decade, NGS technologies have moved at a rapid pace, dramatically reducing costs, and making genome sequencing more routine. What was once unthinkable is now possible. However, most genomes are still sequenced from DNA extracted from multiple cells, which misses differences between cells that could be crucial in controlling gene expression, cell behavior, and drug response. Still, challenges for single-cell sequencing remain, including cell isolation, DNA amplification, and bioinformatics. As the techniques are being refined, subtle differences between cells, such as the tiny genomic rearrangements, will emerge. CHI's Single-Cell Sequencing conference focuses on the links between cell variation in tissues and organ function and further elucidates the origins of diseases. << less
Over the past decade, NGS technologies have moved at a rapid pace, dramatically reducing costs, and making genome sequencing more routine. What was once unthinkable is now possible. However, most genomes are still sequenced from DNA extracted from multiple cells, which misses differences between cells more >>
ELRIG are now preparing for the 7th Annual Drug Discovery Conference, which will be held at Manchester Central on 3rd & 4th September 2013.
The 2013 programme will contain presentations from leading scientists across European Drug Discovery, covering innovations and advances in basic and translational aspects of drug discovery: covering topics such as Innovations in Assay Development, through Oncology Drug Discovery, Macromolecules, Safety & DMPK Screening, Sample Management, Stem Cells, and Stratified Medicine.
Each year, this conference provides a fantastic communication and learning opportunity for scientists engaged at the leading edge of drug discovery, whether in Academia, Biotech or Pharma. As with our highly successful meeting in 2012, attendees will hear world class speakers discussing the challenges and opportunities facing drug discovery scientists today. Drug Discovery '13 will include a scientific poster session, networking sessions, and a large vendor exhibition.
In 2013 the Drug Discovery Symposium will encompass eight Scientific Sessions.
• Target & Biomarker Identification & Validation • Advanced Cell Technologies • In Vitro DMPK & Saftey Screening • Macromolecules as Therapeutics • Innovations In Assay Development & Screening • Science Led Sample Management - 'putting the horse before the cart' • Oncology Drug Targets - 'Where Next?' • Macromolecules as Tools for Discovery & Target Validation
ELRIG are now preparing for the 7th Annual Drug Discovery Conference, which will be held at Manchester Central on 3rd & 4th September 2013.
The 2013 programme will contain presentations from leading scientists across European Drug Discovery, covering innovations and advances in basic and translational more >>
Molecular Medicine Congress will provide the latest novel applications in molecular mechanisms and therapeutic developments. It will also offer new ideas and approaches for research and offer the opportunity for scientists to collaborate with the experts in this field. Our panel of distinguished speakers will present their recent discoveries and most updated scientific information, which will make for a very exciting and rewarding conference to attend.
Agenda Topics: Diagnostic Applications of Next Gen Sequencing Biomarkers and Applications of Exosomes << less
Molecular Medicine Congress will provide the latest novel applications in molecular mechanisms and therapeutic developments. It will also offer new ideas and approaches for research and offer the opportunity for scientists to collaborate with the experts in this field. Our panel of distinguished speakers more >>
SELECTBIO's Stem Cells & Cell Therapy Summit is focused on providing an up-to-date expansive view of the current marketplace focused primarily on the latest research and commercial trends in the utility of cells as therapeutics. Included in this definition are cellular therapy and immunotherapy, as well as tissue engineering and regenerative medicine.
The goal of this summit is to bring together speakers presenting different aspects of the business landscape for the broader cellular therapy field and integrating these presentations to provide a comprehensive picture of the current market landscape.
In 2013, our focus in this inaugural summit is on "Stem Cells & Cellular Therapy."
All registered delegates to this summit receive an electronic copy of the Select Biosciences’ Cellular Therapy, Cord Blood, and iPSCs 2013 Market Report [publication date: January 2013]. << less
SELECTBIO's Stem Cells & Cell Therapy Summit is focused on providing an up-to-date expansive view of the current marketplace focused primarily on the latest research and commercial trends in the utility of cells as therapeutics. Included in this definition are cellular therapy and immunotherapy, as more >>
SELECTBIO's Inaugural Exosomes and Circulating Biomarkers 2013 Summit Focuses on Cutting-Edge Science and Presentations from Academic and Industrial Researchers.
This conference brings together basic biology of exosomes coupled with their emerging potential utility as carriers of cellular cargo and, therefore, representing a treasure trove of biomarkers for the development of diagnostics in the future.
This conference will include presentations, as well as panel discussions, facilitating exchange of unpublished information, as well as cross-pollination with delegates from other conference tracks co-located with this event.
Finally, this conference brings together other classes of circulating biomarkers in an effort to provide an en bloc view of the current state of this field. << less
SELECTBIO's Inaugural Exosomes and Circulating Biomarkers 2013 Summit Focuses on Cutting-Edge Science and Presentations from Academic and Industrial Researchers.
This conference brings together basic biology of exosomes coupled with their emerging potential utility as carriers of cellular cargo and, more >>
The Lab-on-a-Chip World Congress will bring together leaders from both academia and industry to discuss innovative developments in this exciting field. With presentations exploring the latest advances in microfluidics and microfabrication, attention will also be given to some of the many applications of Labs-on-Chips, from the enhancement of life science research, to taking diagnostics to the point of need.
The conference will be co-located with Microarray World Congress, Molecular Diagnostics World Congress and Single Cell Analysis Summit. Registered delegates will have access to all four meetings ensuring a very cost-effective trip. << less
The Lab-on-a-Chip World Congress will bring together leaders from both academia and industry to discuss innovative developments in this exciting field. With presentations exploring the latest advances in microfluidics and microfabrication, attention will also be given to some of the many applications more >>
This conference will discuss the wide range of cutting edge research being conducted using Microarray technologies in various scientific fields. Focusing on areas such as DNA / Protein expression profiling and genotyping, tissue arrays for histological analysis and biomarker discovery, an overview of the diverse work being carried out in this important field will be given.
Across both the conference and exhibition we also aim to keep researchers in the field up to date with the latest microarray tools and analytical techniques available.
Agenda Topics
Advances in DNA Arrays Advances in Lipid and Tissue Arrays Advances in Protein and Antibody Arrays Bioinformatics for Microarrays Biomarker Validation Emerging Technologies Molecular Diagnostics
Call for Posters
You can present your research on a poster while attending the meeting. Submit an abstract for consideration now!
Poster Submission Deadline: 31 August 2013 << less
This conference will discuss the wide range of cutting edge research being conducted using Microarray technologies in various scientific fields. Focusing on areas such as DNA / Protein expression profiling and genotyping, tissue arrays for histological analysis and biomarker discovery, an overview of more >>
Today, innovation is essential for the rapidly evolving diagnostics landscape. While point-of-care testing has the potential to streamline healthcare and improve clinical outcomes, regulators, and clinicians must be creative to translate this potential into a reality. Point-of-Care Diagnostics World Congress will provide an overview of the point-of-care testing landscape, from novel technologies to regulatory approval. Physicians will offer their perspective on point-of-care adoption in the clinical setting as well as in the global health environment. The aim of this meeting is to bring together life science researchers that work at the interface between biology and chemistry to discuss problems, highlight solutions and facilitating collaborations.
The conference will be co-located with Single Cell Analysis Summit, Microarray World Congress and Lab-on-a-Chip World Congress. Registered delegates will have access to all four meetings ensuring a very cost-effective trip. << less
Today, innovation is essential for the rapidly evolving diagnostics landscape. While point-of-care testing has the potential to streamline healthcare and improve clinical outcomes, regulators, and clinicians must be creative to translate this potential into a reality. Point-of-Care Diagnostics World more >>
For the third year running, this interactive forum, organised by Dr Hakim Djaballah, Director of the HTS Core Facility at Memorial Sloan-Kettering Cancer Center, will continue to provide delegates the opportunity to learn as well as share experiences about drug discovery in general, academic screening operations, academia-industry collaborative efforts, and recent trends from the industry service-providers for HTS, chemical libraries, high content screening and RNAi technologies. Whether delegates are looking to expand their basic knowledge, engage in discussions with thought leaders during the afternoon panel discussion sessions, or simply requiring more of an insight to aid and foster future collaborations, this workshop is highly recommended to anyone working in or having an interest in basic sciences and discovery from academia, research institutes, biotech and Pharma companies.
Poster Submission Deadline: 17 August 2013 << less
For the third year running, this interactive forum, organised by Dr Hakim Djaballah, Director of the HTS Core Facility at Memorial Sloan-Kettering Cancer Center, will continue to provide delegates the opportunity to learn as well as share experiences about drug discovery in general, academic screening more >>
CANCER VACCINES 18th September to 19th September 2013, London, United Kingdom
SMi proudly presents the 2nd annual conference on Cancer Vaccines taking place on 18th and 19th September, London. This year’s event aims to focus on innovation and novel strategies within the field, the regulatory environment, and the future direction of cancer vaccines; as well as offering current preclinical and clinical outlook, data, and case studies.
As cancer is still one of the greatest causes of human mortality it is a very attractive target for vaccination. Despite a dramatic increase in research within cancer vaccines in the last decade, there is still a need for more effective therapies to maximise cancer survival rates. Novel strategies for target selection, vaccine design, immunostimulatory therapies, and other biologics are constantly being developed and improved.
The conference, now in its 2nd year, annual Cancer Vaccine conference will examine not only the current clinical data but also the new innovations within the field. This informative event will draw from expert opinions, groundbreaking data, and regulatory factors to look to the future and assess where the field is advancing. This really is a unique event not to be missed.
Benefits of Attending: • Explore innovative and novel strategies, approaches, and vaccines within the field. • Discover future trends, the direction of the field, and combination strategies in both preclinical and clinical situations. • Evaluate the regulatory environment and the subsequent impact on cancer vaccine development. • Consider current trial data, clinical developments, and successful therapeutic vaccines • Learn from successes, failures, and challenges from experts in the field, and apply to optimise vaccine development
Speakers include: • Alex Kudrin, Medical Assessor, Biologicals Licensing, MHRA • Kevin Pollock, Senior Epidemiologist, NHS National Services Scotland • Martin Glennie, Professor of Immunochemistry, University Of Southampton • Pierre van der Bruggen, Group Leader, Ludwig Institute for Cancer Research • Rose-Ann Padua, Research Director, INSERM • Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck Serono
CANCER VACCINES 18th September to 19th September 2013, London, United Kingdom
SMi proudly presents the 2nd annual conference on Cancer Vaccines taking place on 18th and 19th September, London. This year’s event aims to focus on innovation and novel strategies within the field, the regulatory environment, more >>
With the ongoing heated debate on GM crops, SELECTBIO has invited a range of thought leaders to share their perspective on the unique aspects of technology required to enhance the aesthetics, yield, nutrition and disease resistance of varying crops. As well as this, the conference will cover aspects of disease resistance in livestock and how genetic engineering can increase yield of livestock.The next generation of epigenetics, microarrays and sequencing techniques will be discussed with reference to fascinating current research.
Agenda Topics
Disease resistance in livestock Enhancing plant resistance to disease Genetic engineering to increase yield from livestock Optimisation of growth for food and biofuel RNA silencing mechanisms in plants The use of microarrays and bioinformatics
With the ongoing heated debate on GM crops, SELECTBIO has invited a range of thought leaders to share their perspective on the unique aspects of technology required to enhance the aesthetics, yield, nutrition and disease resistance of varying crops. As well as this, the conference will cover aspects more >>
The Pharmaceutical industry is utilizing a plethora of novel approaches, techniques and technologies for Drug Design and Discovery. Use of novel interdisciplinary approaches, developed by understanding integrated biological systems and processes at the functional and molecular levels, has made the discovery process more rational, but complex too. Therefore for optimizing the discovery and development of new molecular entities it is a current practice to follow collaborative research amongst interdisciplinary academic/research centers, government agencies and pharmaceutical industry.
With Dr. Rathnam Chatgutru, (Senior Director, SRI International, USA) serving as Chairperson, Drug Discovery India 2013, will provide an unprecedented opportunity to explore the contract research and collaborative options amongst various research fraternities. Planned open panel discussions and break-out sessions on key thematic areas are sure to energize the participants in defining the drug discovery landscape, especially in the Indian context, and offer ways and means to de-risk the patent cliff experienced by the pharmaceutical industry in recent years.
The conference will be co-located with Genomic & Proteomics Research and Microfluidics & Lab-on-a-Chip meetings will be held at Sheraton Hotel at Brigade Gateway, Bangalore, India. Registered delegates will have unrestricted access to all co-located meetings ensuring a comprehensive learning and sharing experience as well as being financially beneficial for attendees. << less
The Pharmaceutical industry is utilizing a plethora of novel approaches, techniques and technologies for Drug Design and Discovery. Use of novel interdisciplinary approaches, developed by understanding integrated biological systems and processes at the functional and molecular levels, has made the discovery more >>
The event will offer definite advantage to the researchers in the fields of functional genomics, genomic biomarkers, Epigenetics, Next-generation sequencing, miRNA and Non-coding RNA, qPCR, Bioinformatics, Proteomics and Proteome analysis including Chromatography, Mass Spectroscopy and Lab Automation. The program will consist of moderated sessions and engaging an expert panel on research themes at the core of Genomics and Proteomics. The conference will be co-located with Drug Discovery India 2013 and Micro Fluidics & Lab-on-a-Chip India.
Registered delegates will have unrestricted access to all co-located meetings ensuring a comprehensive learning and sharing experience as well as being financially beneficial for attendees. Running alongside the Genomics and Proteomics Research conference will be an Exhibition covering the latest technological advances and associated services within these fields. << less
The event will offer definite advantage to the researchers in the fields of functional genomics, genomic biomarkers, Epigenetics, Next-generation sequencing, miRNA and Non-coding RNA, qPCR, Bioinformatics, Proteomics and Proteome analysis including Chromatography, Mass Spectroscopy and Lab Automation. The more >>
After the inaugural Indian lab Automation (ILA) 2012 at Mumbai, we at SELECTBIO, are delighted to bring together thought leaders in the field of Microfluidics & Lab-on-a-Chip in Bangalore, in September. The event will offer definite advantage to the researchers in the fields of Lab-on-a-Chip, Micro/Nano-fluidics, Optofluidics, Droplet-based Microfluidics, Point of Care Diagnostics, Nanotech on a Chip, Microarray fabrication and application, Multiplexed assays, Single Cell analysis and Robotic Handling & Lab Automation. The program will consist of moderated sessions and engaging an expert panel on research themes at the core of Microfluidics and Lab-on-a-Chip. The conference will be co-located with Drug Discovery India 2013 and Genomics & Proteomics Research, with Registered delegates having unrestricted access to all co-located meetings ensuring a comprehensive learning and sharing experience, as well as being financially beneficial for attendees.
Running alongside the Microfluidics & Lab-on-a-Chip India conference will be an Exhibition covering the latest technological advances and associated services within these fields. << less
After the inaugural Indian lab Automation (ILA) 2012 at Mumbai, we at SELECTBIO, are delighted to bring together thought leaders in the field of Microfluidics & Lab-on-a-Chip in Bangalore, in September. The event will offer definite advantage to the researchers in the fields of Lab-on-a-Chip, Micro/Nano-fluidics, more >>
Diabetes: Secondary Complications, Regulation and Innovation 1 – 2 Oct 2013 | Marriott Hotel, Regents Park London, UK
Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculty unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease.
SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
“This conference is an excellent one stop shop to up-skill on current issues in diabetes therapy. I’m happy to chair what will no doubt be a very stimulating session.” – Phil Ambery, Medical Director, GlaxoSmithKline
Key Reasons to Attend:
• Receive clinical updates on novel GLP1 receptor agonists, and SLGT2 and DPP-4 inhibitors • Utilise biomarkers and imaging for the development of novel therapies for diabetes • Discuss new therapeutic targets to reduce hypertension, hyperkalaemia and endothelial inflammation in diabetes • Remain abreast of new EU and FDA guidelines on clinical trials on risk-benefit assessment • Capitalise on the effects of targeting RAAS, CCN2 and CCN3 inhibitors • Review clinical results from the DEMAND study
Key Speakers Include:
• James F. List, Vice President and Full Development Lead, Dapagliflozin, Bristol-Myers Squibb • John Wilding, Professor of Medicine & Honorary Consultant Physician, Head of Department of Obesity and Endocrinology, University of Liverpool Hospital • Martin Siman, Director, Design and Interpretation Centre of Excellence, AstraZeneca • Philip Ambery, Director, Clinical Development, GlaxoSmithKline • Sandra Souza, Team Lead, Molecular Biomarkers, PPDM , Merck Sharp & Dohme
Diabetes: Secondary Complications, Regulation and Innovation, promises to be a unique platform for networking, problem solving and learning from timely case studies. This really is a unique event not to be missed.
Contact John Collins: Email: jcollins@smi-online.co.uk Tel: +44 (0)207 827 6734 << less
Diabetes: Secondary Complications, Regulation and Innovation 1 – 2 Oct 2013 | Marriott Hotel, Regents Park London, UK
Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculty unite the fields more >>
Since the completion of the Human Genome in 2003, there have been constant challenges to genomic research technologies and public health strategies. These challenges, along with some tangible breakthroughs in the field of genomics, will be discussed at this meeting, providing you with an improved awareness of New Applications in PCR & Next-Generation Sequencing, and Epigenetics, microRNAs and Non-coding RNAs in Disease.
The tracks, and topics at this meeting will be: Epigenetics, microRNAs and non Coding RNAs in Disease – Topics: • Chromatin Mechanisms in Epigenetics • Epigenetics in Disease • Epigenetics in Therapy Development • Epigenetics Research Presentations • Epigenetics Tools & Technologies • Epigenetics-based Biomarkers • Imprinting Epigenetic Memory • lncRNAs: Association with Cancer and Other Disease Classes • microRNA Biology • microRNA in Diagnostics Development/Biomarker Applications • microRNA-based Therapeutics • MicroRNAs as Markers for Drug Toxicity • New Epigenetic Targets • Technologies for Studying microRNAs vs. lncRNAs New Applications of NGS and PCR • 3rd Generation Sequencing Technologies • Applications: Informing Diagnosis & Treatment • Data Analysis and Storage • Detection of Tumour Cells • Expression Profiling • High Resolution Melt • qPCR in Diagnostics • Sequencing Platforms and Methods • Single Cell qPCR << less
Since the completion of the Human Genome in 2003, there have been constant challenges to genomic research technologies and public health strategies. These challenges, along with some tangible breakthroughs in the field of genomics, will be discussed at this meeting, providing you with an improved awareness more >>
SMi’s highly respected and eagerly anticipated 10th Annual Point of Care: Innovations of the Future conference comes to London for what promises to be a highly thought provoking and thrilling event. Join a plethora of highly respected speakers as they discuss topics ranging from the analysis of how the future of Point of Care testing will look and change over the next decade to the different strategies medical trusts are putting in place to increase the use of Point of Care testing within the patient care setting. Identify potential gaps in the market for new technologies and learn how to successfully implement these in a highly competitive market place.
This year’s Point of Care: Innovations of the Future conference will focus on technologies aimed at treating infectious diseases, with a focus on the rapid identification and ‘on the spot’ diagnosis of infectious diseases such as HIV and TB. This year’s event will take a look at what strategies different healthcare trusts are implementing to increase the usage of Point of Care testing and diagnosis at the site of the patient. << less
SMi’s highly respected and eagerly anticipated 10th Annual Point of Care: Innovations of the Future conference comes to London for what promises to be a highly thought provoking and thrilling event. Join a plethora of highly respected speakers as they discuss topics ranging from the analysis of how more >>
Towards Re-designed Synthetic Systems ... CONFERENCE OVERVIEW: The ability to produce proteins (as reagents or biotherapeutics) of sufficient quality and quantity is important for the academic and industrial sectors. The use of eukaryotic cells as hosts for expression and recovery of recombinant cellular, membrane or secreted proteins has developed markedly over the past decade. This conference brings together academic and industrial researchers working on eukaryotic cells as protein expression hosts, and will address our current fundamental understanding about molecular events that determine productivity and quality attributes in the use of specific cell hosts for specific protein product categories. In particular, the conference will focus on the biology of existing host cells (in terms of competencies for protein expression), structural features associated with success of expression of specific proteins (including the relationships between specific proteins and host cells) and how both host cell and desired proteins may be engineered to generate new synthetic systems for enhanced product expression. The two day conference will consist of presentations by plenary speakers, workshop sessions with invited speakers and speakers selected from offered abstracts and a poster session. Participation will be strictly limited to 220 attendees to enable networking and informal discussion. << less
Towards Re-designed Synthetic Systems ... CONFERENCE OVERVIEW: The ability to produce proteins (as reagents or biotherapeutics) of sufficient quality and quantity is important for the academic and industrial sectors. The use of eukaryotic cells as hosts for expression and recovery of recombinant more >>
Get the App
Get this event information on your mobile by going to the appstore or google play and search for 'eventflo'
type the following in your web browser: webapp.myeventflo.com
